Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Triple Negative ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3705293 ◽

2020 ◽

Author(s):

Biyun Wang ◽

Tao Sun ◽

Yannan Zhao ◽

Shusen Wang ◽

Jian Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz100.047 ◽

2019 ◽

Vol 30 ◽

pp. iii63

Author(s):

V. Boni ◽

C. Alemany ◽

J.L. Meisel ◽

R. Sinha ◽

D. Sterrenberg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs19-pd1-06 ◽

2020 ◽

Cited By ~ 2

Author(s):

Hyo (Heather) Han ◽

Sami Diab ◽

Carlos Alemany ◽

Reva Basho ◽

Ursa Brown-Glaberman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase 1B ◽

357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.459 ◽

2020 ◽

Vol 31 ◽

pp. S393

Author(s):

J. Cortés ◽

S. Diab ◽

R.K. Basho ◽

M. Oliveira ◽

T. Pluard ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽

282MO Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.384 ◽

2020 ◽

Vol 31 ◽

pp. S354

Author(s):

X. Hu ◽

B. Wang ◽

J. Zhang ◽

Z. Wang ◽

T. Sun ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30689-8 ◽

2020 ◽

Vol 21 (1) ◽

pp. 44-59 ◽

Cited By ~ 112

Author(s):

Peter Schmid ◽

Hope S Rugo ◽

Sylvia Adams ◽

Andreas Schneeweiss ◽

Carlos H Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30754-3 ◽

2021 ◽

Vol 22 (4) ◽

pp. 499-511 ◽

Cited By ~ 1

Author(s):

Eric P Winer ◽

Oleg Lipatov ◽

Seock-Ah Im ◽

Anthony Goncalves ◽

Eva Muñoz-Couselo ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.01.065 ◽

2021 ◽

Author(s):

A. Brufsky ◽

S.B. Kim ◽

Ž. Zvirbule ◽

A. Eniu ◽

J. Mebis ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Primary Analysis ◽

Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Chemotherapy ◽

10.1159/000356156 ◽

2013 ◽

Vol 59 (3) ◽

pp. 207-213 ◽

Cited By ~ 4

Author(s):

Yuqian Liao ◽

Ying Fan ◽

Yiye Wan ◽

Jun Li ◽

Lixiang Peng

Keyword(s):

Breast Cancer ◽

Pilot Study ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Limited Efficacy ◽